Table 1.
Demographics and clinical characteristics at time of first brolucizumab injection
| Overall | Eyes that developed IOI-related AEs after brolucizumab initiation | |||
|---|---|---|---|---|
| Patients N = 414 |
Eyes N = 482 |
Patients N = 21 |
Eyes N = 22 |
|
| Age (years), mean (SD) | 81.1 (9.1) | – | 80.8 (9.8) | – |
| Sex | ||||
| Female, n (%) | 240 (58.0)* | – | 14 (66.7) | – |
| VA (ETDRS letters), mean (SD) | – | 58.3 (21.6) | – | 61.4 (17.7) |
| Anti-VEGF treatment status | ||||
| Treatment-naïve, n (%) | – | 22 (4.6%) | – | 1 (4.5%) |
| Prior-treated, n (%) | – | 460 (95.4) | – | 21 (95.5%) |
| Last injection interval before switch to brolucizumab in prior-treated eyes | ||||
| Days, mean (SD) | – | 46.8 (26.0) | – | 45.1 (13.4) |
| CMT | ||||
| n (%) | – | 409 (84.9) | – | 19 (86.4) |
| µm, mean (SD) | – | 297.2 (102.9) | – | 289.5 (114.4) |
| IRF present, n (%) | – | 115 (23.9) | – | 3 (13.6) |
| SRF present, n (%) | – | 288 (59.8) | – | 13 (59.1) |
| PED present, n (%) | – | 304 (63.1) | – | 12 (54.5) |
*Sex unknown for three patients. CMT, central macular thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; IRF, intraretinal fluid; PED, pigment epithelial detachment; SD, standard deviation; SRF, subretinal fluid; VA, visual acuity